Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 2CNS 2NET 1Head & Neck 1

Conditions

Neuroendocrine Tumors 9Carcinoma, Neuroendocrine 2Carcinoid Tumor 2Thyroid Carcinoma, Anaplastic 1Small Cell Lung Carcinoma 1Pheochromocytoma 1Paraganglioma 1Non functioning pancreatic endocrine tumor 1Metastatic Digestive System Neuroendocrine Tumor G1 1Gastro-enteropancreatic neuroendocrine tumor 1Clear-cell metastatic renal cell carcinoma 1Carcinoma, Renal Cell 1Adenoma, Islet Cell 1Adenocarcinoma 1

Interventions

lutetium Lu 177 dotatate 5gallium Ga 68 dotatate 33-Iodobenzylguanidine 3Magnetic Resonance Spectroscopy 2177Lu-octreotide, DOTA(0)-Tyr(3)- 2vandetanib 1olaparib 1fludarabine phosphate 1copper dotatate CU-64 1cabozantinib 1atezolizumab 1Specimen Handling 1Lutetium-177 1Lutetium 1Iodine-131 1Interleukin-13 1Fluorodeoxyglucose F18 1Everolimus 1Erlotinib Hydrochloride 1Cyclophosphamide 1Biopsy 190Y-octreotate, DOTA(0)-Tyr(3)-Thr(8)- 13-fluorobenzylguanidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Paraganglioma × cabozantinib × NET × Clear all
NCT04400474 2025-06-19

CABATEN

Grupo Espanol de Tumores Neuroendocrinos

Phase 2 Completed
93 enrolled 17 charts
CNSEndocrineHead & NeckNET

Adenocarcinoma, Paraganglioma, Pheochromocytoma, Neuroendocrine Tumors, Thyroid Carcinoma, Anaplastic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡